
What We're Reading: Fetal Tissue Restrictions; Opioid Maker Pays Up; Medicaid Work Requirements and Employment
Granting the wishes of anti-abortion groups, the Trump administration announced it will end fetal tissue research by government scientists; Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell a powerful fentanyl spray; Medicaid enrollees who would potentially be subject to Medicaid work requirements are likely to face barriers to employment.
Trump Administration Tightens Restrictions on Fetal Tissue Research
The Trump administration said Wednesday that they have discontinued all internal research that involves fetal tissue, putting an end to fetal tissue research by government scientists. The announcement was welcome news to anti-abortion activists, as fetal tissue is obtained through elective abortions. According to a
Opioid Maker Agrees to Pay $225 Million to Resolve Federal Probes
Opioid manufacturer Insys Therapeutics has agreed to pay $225 million to settle federal investigations into allegations that the manufacturer paid kickbacks and used other illegal tactics to sell Susbys, a fentanyl spray meant for patients with cancer with severe pain,
Many Targeted by Work Requirements Face Barriers to Employment
Medicaid enrollees who would potentially be subject to Medicaid work requirements implemented by their state are more likely to face barriers to sustained employment compared with privately insured adults, according to a brief
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.